The Effectiveness of Air Quality Sensor in Elderly Residential Setting
Launched by THE UNIVERSITY OF HONG KONG · Apr 18, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how an air quality sensor can help improve the health of elderly residents living in care homes, especially those with respiratory issues. The main goal is to see if monitoring the air quality in real-time and taking steps to improve it can reduce symptoms like coughing and shortness of breath. The researchers are also looking at whether better air quality can lower heart rates and blood pressure, along with understanding what actions can be taken to enhance air quality and how effective those actions are.
To participate in this study, residents must live on the floor where the air quality sensors will be installed and preferably have some breathing problems. Care staff who look after the residents can also be involved. There are no specific exclusions for residents or staff, which makes it easier for many to join. Participants will be monitored for changes in their health, and the researchers will also track how often residents feel unwell or need hospital care. Overall, this study aims to find out if improving air quality can lead to better health outcomes for elderly individuals in residential settings.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- Inclusion criteria of residents:
- • Reside on the floor of the study site that will be installed with the air quality sensors, and
- • Preferably have respiratory and pulmonary illnesses
- Inclusion criteria of care staff:
- • Responsible for the general care of the participants
- Exclusion Criteria:
- Exclusion criteria of residents and care staff:
- • None
About The University Of Hong Kong
The University of Hong Kong (HKU) is a leading research institution dedicated to advancing medical knowledge and improving healthcare outcomes through innovative clinical trials. With a commitment to excellence in research and education, HKU collaborates with various stakeholders, including healthcare providers and industry partners, to conduct rigorous and ethically sound clinical studies. The university's diverse expertise and state-of-the-art facilities enable it to explore a wide range of therapeutic areas, contributing to the global pursuit of scientific advancement and the development of novel treatment strategies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hong Kong, , Hong Kong
Patients applied
Trial Officials
Yee Tak Cheung, PhD
Principal Investigator
The University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported